Prostatic ductal adenocarcinoma: an unusual case of a rare prostate cancer

Abstract

A 65 year old gentleman was referred with symptoms of haematuria and haematospermia in association with an elevated prostate specific antigen (PSA). He was investigated with a flexible cystoscopy, Ultrasound scan and a computed tomography (CT) of his abdomen and pelvis. These failed to reveal any abnormality. Magnetic resonance imaging (MRI) revealed a Prostate Imaging Reporting and Data System PIRADS 2 lesion in the left peripheral gland and PIRADS 3 lesion on the right side posterolaterally at the level of mid gland of the prostate. He went on to have Transrectal ultrasound biopsies of his prostate (TRUS Bx) that excluded any pathology. On follow up visits his PSA continued to rise and he underwent Template biopsies of the prostate. The histological features had no evidence of any Prostatic intraepithelial carcinoma (PIN) or other malignancies. Flexible cystoscopy was repeated due to his persistent haematospermia. This showed prominent papillary lesions over his verumontanum and prostatic urethra. Biopsies from these areas revealed Ductal Adenocarcinoma of the Prostate (DACP). A subsequent staging MRI revealed unchanged appearance of the PIRADS2 nodule. There was however some low signal extending into the right seminal vesicle which is more pronounced than on the previous scan reported as PIRADS3. Subsequent mapping Template biopsies and Transurethral biopsies revealed a Gleason 4+4 DCAP. A staging CT and bone scan excluded any metastasis. He went on to receive an open radical prostatectomy and pelvic lymph node dissection as a curative treatment for his locally advanced disease.

Keywords

Ductal Adenocarcinoma of the Prostate / Prostate specific antigen / Flexible cystoscopy / Prostatic intraepithelial carcinoma / PIRADS / Gleason

References

[1] Leibovici D, Spiess PE, Agarwal PK. Prostate cancer progression in the presence of undetectable or low serum prostate-specific antigen level. Cancer: Interdisciplinary International Journal of the Amer-ican Cancer Society. 2007 Jan; 109(2): 198-204. PMid:17171704. https://doi.org/10.1002/cncr.22372

[2] Melicow MM, Patcher MR. Endometrial carcinoma of prostatic utri-cle (uterus masculinus). Cancer: Interdisciplinary International Jour-nal of the American Cancer Society. 1967; 20: 1715-1722.

[3] Todd MM, Christopher JW, Funda VL. Ductal adenocarcinoma of the prostate: increased mortality risk and decreased PSA secretion. The Journal of Urology. 2010; 184(6): 2303-2307. PMid:20952027. https://doi.org/10.1016/j.juro.2010.08.017

[4] Bock BJ, Bostwick DG. Does prostatic ductal adenocarcinoma ex-ist?American Journal of Surgical Pathology. 1999 Jul; 23(7): 781-5. PMid:10403300. https://doi.org/10.1097/00000478-199907000-00005

[5] Fuse H, Komiya A, Nozaki T, et al. Hematospermia: etiology, di-agnosis, and treatment. Reproductive Medicine and Biology. 2011 Oct; 10(3): 153-9. PMid:29699089. https://doi.org/10.1007/s12522-011-0087-4

[6] Magoha GA, Magoha OB. Aetiology, diagnosis and management of haemospermia: a review. East African Medical Journal. 2008; 84(12). https://doi.org/10.4314/eamj.v84i12.9596

[7] Ng YH, Seeley JP, Smith G. Haematospermia as a presenting symp-tom: outcomes of investigation in 300 men. The Surgeon: Journal of the Royal Colleges of Surgeons of Edinburgh and Ireland. 2013; 11(1): 35-38. PMid:22682581. https://doi.org/10.1016/j.surge.2012.04.004

[8] Tantan L, Yingmei W, Ru Z. The update of prostatic ductal adenocar-cinoma. Chinese Journal of Cancer Research. 2016; 28(1): 50-57.

[9] Seipel AH, Wiklund F, Wiklund NP. Histopathological features of ductal adenocarcinoma of the prostate in 1,051 radical prostatec-tomy specimens. Virtuous Archiv:The European Journal of Pathology. 2013 Apr; 462(4): 429-36. PMid:23443941. https://doi.org/10.1007/s00428-013-1385-5

[10] Perrapato SD, Shah PC, Huben RP. Locally recurrent endometrioid adenocarcinoma of the prostate after radical prostatectomy. The Jour-nal of Urology. 1991 Sep; 145(2): 373-375. https://doi.org/10.1016/S0022-5347(17)38345-3

[11] Tu SM, Lopez A. Leibovici D Ductal adenocarcinoma of the prostate: clinical features and implications after local therapy. Cancer: Inter-disciplinary International Journal of the American Cancer Society. 2009 Jul; 115(13): 2872-80. PMid:19402048. https://doi.org/10.1002/cncr.24326

[12] Kumar A, Mukherjee SD. Metastatic ductal carcinoma of the prostate: a rare variant responding to a common treatment. Canadian Urologi-cal Association journal 2010; 4(2): 50-4. https://doi.org/10.5489/cuaj.830